The recent hantavirus outbreak linked to a cruise ship has reignited worldwide interest in the endeavors of Chilean researchers aiming to create a treatment for this perilous virus.
Years back, Chilean scientists achieved significant advancements in the creation of antibodies effective against the Andes strain, the only variant known to transmit between humans. However, a lack of funding and the Covid-19 pandemic forced these efforts to a halt.
The outbreak aboard the MV Hondius cruise ship, which traveled from Argentina to Europe, has resulted in infections and multiple fatalities. Consequently, the World Health Organization (WHO) issued warnings and raised international alarm over the virus's spread.
This pioneering research, spearheaded by Marcela Barria and her team at Universidad de Concepcion, has shown that certain antibodies can effectively neutralize the virus in lab conditions. Subsequent trials on animals also revealed promising findings, where one antibody managed to completely eradicate the virus from the lungs.
Collaborating with international entities, including the US National Institutes of Health, Germany's Robert Koch Institute, and Ichor Biologics based in New York, the Chilean team made remarkable strides.
In 2018, their research disclosed two monoclonal antibodies that successfully combat the virus. By 2021, one treatment received orphan drug classification from the US FDA, which aids expedited medical progression.
Despite this momentum, the research faced obstacles before entering human trials, requiring nearly $7 million in funding. Resources were diverted to address priorities during the pandemic, postponing vital work.
Barria emphasized that while significant milestones were reached, they currently lack the required infrastructure and investment needed to advance clinical trials.
In 2026, Chile recorded 39 hantavirus cases and 13 deaths, whereas Argentina reported 42 infections by early May. Health authorities warn that hantavirus remains a significant risk in South America, particularly in southern regions.
Symptoms often mimic flu, including fever, fatigue, and muscle aches, potentially escalating to severe respiratory failure, necessitating intensive care.
Currently, there is no specific treatment, but early detection can enhance survival rates, with fatality rates soaring to 40% in severe cases.
Barria's team is actively researching immune responses and antibody persistence while seeking funds to resume human trials. They estimate it may take up to two years to return to their pre-pandemic research phase.
This latest outbreak has once again spotlighted the urgent need for effective treatments and vaccines to prevent future hantavirus crises.
A strong smell at a shopping mall in Tokyo triggered a major emergency response with at least 19 pe
Recent missile strikes in Ukraine have escalated regional tensions, prompting urgent calls for inter
A tense exchange between Donald Trump and Xi Jinping during high-level talks has raised questions ab
Indigenous treaty rights and constitutional protections are becoming major obstacles in Alberta’s gr
